Short answer
Vaxcyte, Inc. (PCVX) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$284M
- −70.7% YoY · +11.3% QoQ
- EPS (diluted)
- −$1.96
- −60.7% YoY · +14.8% QoQ
Source: XBRL data from the Vaxcyte, Inc. (PCVX) Q2 2026 10-Q on SEC EDGAR. USD.
Vaxcyte, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved products or commercial sales
- Net loss $284.3M for three months ended June 30, 2026
- Cash, equivalents and investments $2.5B; sufficient through at least 12 months
- VAX-31 Phase 3 trials fully enrolled; 6,191 adults dosed, including approximately 3,500 receiving VAX-31
- Topline VAX-31 OPUS-1 data expected fourth quarter 2026; OPUS-2 and OPUS-3 data expected first half 2027
Risk Factors
- No explicit new risk factor identified; filing reiterates previously described development, regulatory, and financing risks
- Updated regulatory risk: FDA may challenge VAX-31’s Phase 3 CMC strategy, delaying approval and increasing costs
- Financial risk: $2.5 billion cash, equivalents, and investments fund operations for at least 12 months from filing
- Financial performance risk: $604.9 million six-month net loss and $2.8 billion accumulated deficit as of June 30, 2026
- Operational risk: manufacturing-process changes or scale-up failures could delay VAX-31, VAX-24, or other candidates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vaxcyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.